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Abstract
Background: Activation of the NLRP3 inflammasome in gout amplifies the inflammatory response and mediates
further damage. In the current study, we assessed the therapeutic effect of OLT1177, an orally active NLRP3
inflammasome inhibitor that is safe in humans, in murine acute arthritis models.
Methods: Zymosan or monosodium urate (MSU) crystals were injected intra-articularly (i.a.) into mouse knee joints
to induce reactive or gouty arthritis. Joint swelling, articular cell infiltration, and synovial cytokines were evaluated
25 hours and 4 hours following zymosan or MSU challenge, respectively. OLT1177 was administrated
intraperitoneally by oral gavage or in the food by an OLT1177-enriched diet.
Results: OLT1177 reduced zymosan-induced joint swelling (p < 0.001), cell influx (p < 0.01), and synovial levels of
interleukin (IL)-1β, IL-6, and chemokine (C-X-C motif) ligand 1 (CXCL1) (p < 0.05), respectively, when compared with
vehicle-treated mice. Plasma OLT1177 levels correlated (p < 0.001) dose-dependently with reduction in joint
inflammation. Treatment of mice with OLT1177 limited MSU crystal articular inflammation (p > 0.0001), which was
associated with decreased synovial IL-1β, IL-6, myeloperoxidase, and CXCL1 levels (p < 0.01) compared with vehicle-
treated mice. When administrated orally 1 hour after MSU challenge, OLT1177 reduced joint inflammation,
processing of IL-1β, and synovial phosphorylated c-Jun N-terminal kinase compared with the vehicle group. Mice
were fed an OLT1177-enriched diet for 3 weeks and then challenged i.a. with MSU crystals. Joint swelling, synovial
IL-1β, and expression of Nlrp3 and Il1b were significantly reduced in synovial tissues in mice fed an OLT1177-
enriched diet when compared with the standard diet group.
Conclusions: Oral OLT1177 is highly effective in ameliorating reactive as well as gouty arthritis.
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Background
Severe inflammation of articular joints is the hallmark of
acute arthritides such as gouty arthritis and reactive
arthritis. These types of acute inflammatory arthritis are
initiated either by sterile triggers, such as in gout, or
microbial agents, as in reactive arthritis. In the case of
gout, monosodium urate (MSU) crystal deposits and a
second signal are needed to trigger joint inflammation [1].
Reactive or septic arthritis is mostly caused by microor-
ganisms such as group A Streptococcus pyogenes, Chla-
mydia trachomatis, Campylobacter, Salmonella, Shigella,
or Yersinia [2]. Reactive arthritis occurs as a response to
infections in the genitals or the gut. Of interest, these
forms of acute arthritis occur mainly in males [3]; why
males are more susceptible to gouty arthritis or reactive
arthritis remains unknown.
A common feature of acute arthritides is the marked
influx of neutrophils into the joint cavity [4]. This
process is initiated mainly by the production and release
of proinflammatory mediators, such as cytokines and
chemokines, by the synovial lining cells. Interleukin
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(IL)-1β, IL-6, and IL-8 are the main mediators impli-
cated in the onset of acute arthritis, both in humans and
in murine models [5–7]. Decades ago, IL-1β was reported
as the prominent cytokine for inducing production of IL-6
and IL-8 [8, 9]. IL-8 is the classical chemokine that drives
large numbers of neutrophils into sites of infection or
inflammation, and IL-8 has been detected in high concen-
trations in the synovial fluid of patients with acute arthritis
[10]. In murine models of acute arthritis, IL-1β inhibition
during onset of arthritis results in effective suppression of
joint swelling and influx of inflammatory cells [7, 11].
These observations were further underscored by studies
in which models of acute joint inflammation were induced
in IL-1β-deficient mice [11].
In gout and several other forms of arthritis, nucleotide-
binding oligomerization domain-like receptor (NLR) pro-
tein 3 (NACHT, LRR and PYD domains-containing protein
3 [NLRP3], cryopyrin) inflammasome activation is critical
in both the inflammatory phase and the progression of dis-
ease [12]. Inflammasomes are macromolecular complexes
formed in the cytosol of cells in response to various stimuli
[13, 14]. Following activation of the NLRP3 inflammasome,
the intracellular cysteine protease caspase-1 is activated and
generates bioactive IL-1β and IL-18 [15].
We recently reported that OLT1177 (recommended
International Nonproprietary Name [rINN] depansu-
trile) specifically targets the NLRP3 inflammasome
and thereby prevents processing and release of IL-1β
and IL-18 in vitro [16]. OLT1177 is active in vivo
and limits the severity of endotoxin-induced inflam-
mation [16]. The role of IL-1β in rare autoinflamma-
tory diseases, such as familial Mediterranean fever
and cryopyrin-associated periodic syndrome, is long
established using specific inhibitory strategies to pre-
vent IL-1β activity [17, 18]. Gout is a common in-
flammatory joint disorder, and specific inhibition of
IL-1β is approved by the U.S. Food and Drug Ad-
ministration and the European Medicines Evaluation
Agency for reducing the number of gout attacks
[19–21]. Nevertheless, a clinical need, particularly
for the refractory cases, remains unmet [22]. In the
current study, using two distinct murine models of
acute inflammatory arthritis, we validated the ration-
ale for treatment of acute joint inflammation with
the NLRP3 inflammasome inhibitor OLT1177.
Methods
OLT1177 treatments
OLT1177 was synthesized as described elsewhere [16].
Crystalline OLT1177 was solubilized with sterile saline
for intraperitoneal administrations and with water for
oral gavage studies. OLT1177 dosing solutions were
prepared fresh before each experiment.
Mice
Animal protocols were approved by the University of
Colorado Animal Care and Use Committee. Male C57BL/
6 mice (10–12 weeks of age) were purchased from The
Jackson Laboratory (Bar Harbor, ME, USA) and housed in
the animal facility for at least 7 days before use.
Zymosan-induced arthritis
Knee joints were injected intra-articularly (i.a.) into the
synovial space directly under the patella with 180 μg of
zymosan from Saccharomyces cerevisiae (Sigma-Aldrich,
St. Louis, MO, USA). Briefly, 300 mg of zymosan were
dissolved in 10 ml of sterile saline, boiled three times,
and sonicated to ensure a uniform suspension. Mice
were treated with OLT1177 (60, 200, or 600 mg/kg as
indicated) in 200 μl of saline for intraperitoneal adminis-
tration or in water for oral gavage at 24 hours, 12 hours,
and 1 hour before zymosan injection. Mice received two
additional administrations of the corresponding dose of
OLT1177 at 11 and 23 hours after the zymosan chal-
lenge. Twenty-five hours after the zymosan instillation,
mice were anesthetized, joint swelling was scored, and
knee and synovial tissues were collected for histological
and cytokine analyses.
MSU crystal-induced arthritis
Gouty arthritis was induced by injecting into the right and
left knees of mice 10 μl of a mixture of 300 μg of MSU
crystals, 200 μM C16:0 palmitic acid (Sigma-Aldrich), and
1 mg of bovine serum albumin (Sigma-Aldrich). The
effect of OLT1177 in the gouty arthritis model was tested
using three different OLT1177 treatment protocols.
First protocol
OLT1177 and vehicle were given by oral gavage every
12 hours for five doses. One hour after the last dose, the
MSU suspension was administrated in the knees of the
mice.
Second protocol
OLT1177 and vehicle were administered orally as a sin-
gle dose 1 hour after the induction of gouty arthritis.
Third protocol
The third protocol used a special research diet. Mice were
fed either an OLT1177-enriched diet or a standard food
diet for 3 weeks. The composition of the food was identical
(standard mouse chow), except that OLT1177-enriched
food contained 7.5 g of OLT1177 per kilogram of food.
Food and water were provided ad libitum for the entire
length of the study. Standard and OLT1177-enriched diets
were prepared by Research Diets (New Brunswick, NJ,
USA). Mice that were given i.a. injections with saline and
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not subjected to gouty arthritis were used as sham animals
for the comparison of the joint swelling.
For each dosing protocol, mice were anesthetized, and
the skin over the knee joints was opened so the MSU
mixture could be injected i.a. Mice were killed 4 hours
following MSU crystal instillation. The joint was exposed
and scored macroscopically. Thereafter, knee joints and
synovial tissue specimens were collected for histological
or molecular analysis.
Joint scoring
After the skin was removed from each knee, the joint
(R and L) was scored macroscopically on a scale from
0 to 3, where 0 = no inflammation, 1 = mild inflamma-
tion, 2 = moderate inflammation, and 3 = severe in-
flammation, in increments of 0.25. A score of 0.25
was given when the first signs of swelling and redness
were present. Joint swelling scoring was performed by two
authors without knowledge of the experimental groups.
Sample collection and cytokine measurement
After macroscopic scoring, the entire right knee joint
was removed and fixed in 4% formaldehyde for histo-
logical analysis. The synovial tissue specimens from the
left knee were removed for cytokine measurements.
Briefly, patella with minimal surrounding muscle tissue
and maximal synovial membrane was excised from the
left knee joint. The synovial tissue explants were placed
in 250 μl of 0.5% Triton X-100 (in water) and subjected
to three freeze-thaw cycles to increase the extraction
process. Cytokines were measured in the lysates of synovial
tissues by specific enzyme-linked immunosorbent assays
(R&D Systems, Minneapolis, MN, USA) following the
manufacturer’s instructions. Because of experiment-related
variations in cytokine production in some experiments, the
raw data were calculated as percent changes of cytokine
levels between vehicle-treated and OLT1177-treated mice.
For example, in the zymosan-challenged group, each mean
value in picograms per milliliter for vehicle-treated mice
was set at 100%. For each value of OLT1177-treated mice,
percent change was calculated. The ranges of levels in pi-
cograms per milliliter are indicated in each figure legend.
Histological analysis
The right knee joints were fixed in 4% formaldehyde for
7 days before decalcification using 5% formic acid and
processed for paraffin embedding. Tissue sections (7 μm)
were stained with H&E. Histopathological changes in the
knee joints were scored in the patellar/femoral region in
five semiserial sections by the number of infiltrating cells
in the synovial lining and/or joint cavity on a scale ranging
from 0 to 3. Joint inflammation was graded on decoded
slides by two separate observers.
OLT1177 plasma exposure
OLT1177 was extracted from 50.0 μl of mouse plasma
by a liquid-liquid procedure and quantified in plasma
using gas chromatography (GC) with detection by MS/
MS (Chemic Laboratories, Inc., Canton, MA, USA).
OLT1177-D3 was used as the internal standard. Extrac-
tion started with the addition of 20.0 μl of the internal
standard working solution for all samples. The samples
were vortexed gently, and then 2.0 ml of ethyl acetate
was added. Samples were vortexed, centrifuged, and
placed in an acetone dry ice water bath, where the super-
natant was transferred to clean tubes. The supernatant
was then evaporated to dryness and reconstituted with
N,O-bis(trimethylsilyl)trifluoroacetamide (1:25 vol/vol)
with 1% trimethylchlorosilane/ethyl acetate. Samples were
covered, vortexed, and transferred to clean amber vials.
The extracts were examined by chromatograph on a
DB-17 GC column (J&W Scientific, Folsom, CA, USA).
OLT1177 was detected and quantified by MS/MS in posi-
tive ion mode using an Agilent 7890A GC system (Agilent
Technologies, Santa Clara, CA, USA). A method qualifica-
tion run was performed, and the qualified quantitation
range was 20.0–2000 ng/ml.
Whole-blood culture
Blood was collected in ethylenediaminetetraacetic acid-
coated tubes, and total white blood cell (WBC) counts and
the percentages of monocytes, lymphocytes, and granulo-
cytes were determined using a HemaTrue cell counter
(Heska, Loveland, CO, USA). For the whole-blood cultures,
blood was diluted in RPMI 1640 medium (Mediatech
CellGro; Corning, Corning, NY, USA) (1:), and 200 μl was
added to each round-bottomed well. The microtiter plates
were incubated for 24 hours at 37 °C. After incubation, the
supernatants were removed and frozen at − 80 °C until
assayed for cytokines.
Western blotting
The protein concentration of the synovial tissue extracts
(L) was determined in the clarified supernatants using a
Bio-Rad protein assay (Bio-Rad Laboratories, Hercules, CA,
USA). Proteins were electrophoresed on Mini-PROTEAN
TGX 4–20% gels (Bio-Rad Laboratories) and transferred to
nitrocellulose of 0.45 μm pore size (GE Healthcare Life
Sciences, Marlborough, MA, USA). Membranes were
blocked in 5% dried milk in PBS-Tween 0.5% for 1 hour at
room temperature. Phosphorylated stress-activated protein
kinase/c-Jun N-terminal kinase (JNK) (1:500; Cell Signaling
Technology, Danvers, MA, USA), IL-1β (1:1000, AF-401;
R&D Systems), and NLRP3 (1:1000, Cryo-2; AdipoGen Life
Sciences, San Diego, CA, USA) were used as the primary
antibodies. Peroxidase-conjugated secondary antibodies
and chemiluminescence were used to develop the blots. A
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primary antibody against β-actin (Santa Cruz Biotechnol-
ogy, Dallas, TX, USA) was used to assess protein loading.
Statistical analysis
Statistical significance of differences was evaluated with
a two-tailed Student’s t test using Prism version 6.0 soft-
ware (GraphPad Software, La Jolla, CA, USA). Statistical
significance was set at p < 0.05.
Results
OLT1177 reduces the severity of zymosan-induced
arthritis
Joint swelling and i.a. neutrophil infiltration were assessed
25 hours after injection of zymosan into the knee joints.
Figure 1a depicts the marked knee joint swelling after the
zymosan challenge as compared with the saline-injected
group. In OLT1177-treated mice, the inflammation was







Fig. 1 Effect of OLT1177 on zymosan-induced arthritis. a Representative images of knees from saline injected (Saline), vehicle-treated, and
OLT1177 (200 mg/kg)-treated mice. b Mean ± SEM of joint score (n = 16 per group). c and d H&E-stained histological knee sections from
vehicle- and OLT1177-treated mice. Original magnification 100 ×. e Mean ± SEM of cell influx (n = 5 per group). f–i Mean ± SEM percent change
of interleukin (IL)-1β (range 189–2488 pg/ml), IL-6 (range 100–843 pg/ml), chemokine (C-X-C motif) ligand 1 (CXCL1) (range 169–472 pg/ml), and
tumor necrosis factor (TNF)-α (282–405 pg/ml) in synovial tissue extracts from mice subjected to experimental zymosan-induced arthritis and
treated with OLT1177 (200 mg/kg). Percent change was calculated as described in the Methods section of text. n = 8 per group; **** p < 0.0001,
** p < 0.01, * p < 0.05
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examined cell influx, a hallmark of inflammation and tis-
sue damage, using histological analysis of the knee joint.
H&E staining revealed that mice treated with OLT1177
had a visible reduction in infiltrating cells, predominantly
neutrophils (p = 0.006) (Fig. 1c–e) when compared with
vehicle-treated mice.
We next determined the effect of OLT1177 treatment
on the levels of inflammatory mediators in inflamed
synovial tissue. As depicted in Fig. 1f–h, treatment with
OLT1177 (200 mg/kg) reduced synovial tissue concen-
trations of IL-1β and IL-6 by 55% (p < 0.05) and the
neutrophil chemokine (C-X-C motif ) ligand 1 (CXCL1)
by 30% (p < 0.05). No significant effect was observed in
tumor necrosis factor (TNF)-α levels (Fig. 1i). In addition,
OLT1177 was effective in reducing joint inflammation fol-
lowing zymosan instillation when administrated orally.
Oral gavage of OLT1177 (600 mg/kg) showed a significant
reduction in synovial swelling (p < 0.001) and IL-1β level
(− 70%; p = 0.01) (Additional file 1: Figure S1A and B),
with no effect on TNF-α (Additional file 1: Figure S1C),
when compared with vehicle-treated mice. These
data indicate that OLT1177 reduced cytokine levels,
which was associated with decreased severity of the
zymosan-induced arthritis.
Dose-response suppressive effect of OLT1177 on joint
inflammation in mice with zymosan-induced arthritis
The anti-inflammatory effect of different concentrations
of OLT1177 was evaluated. As depicted in Fig. 2a,
treatment with OLT1177 revealed a dose-dependent
reduction of joint inflammation scores following i.a.
injection of zymosan, with maximal inhibition at 600 mg/kg
(− 63%; p < 0.0001). The different concentrations used of
OLT1177 (60, 200, and 600 mg/kg) corresponded to plasma
levels of 9.22 ± 0.55, 16.73 ± 9.89, and 41.4 ± 3.68 μg/ml, re-
spectively (Fig. 2b). This analysis demonstrates a dir-
ect correlation (p < 0.001) between the reduction in
joint inflammation and the circulating concentration
of OLT1177.
OLT1177 reduces joint inflammation of MSU crystal-
induced gouty arthritis
Next, we examined the effect of OLT1177 in a model of
MSU-induced gouty arthritis. Following i.a. administra-
tion of MSU crystals, severe swelling of the knee joint
was observed in vehicle-treated mice (Fig. 3a). Oral
treatment with OLT1177 (600 mg/kg) showed significant
reduction in joint scores when compared with the ve-
hicle group (75% reduction; p < 0.0001) (Fig. 3b). Histo-
logical analyses of the knee joints showed suppression of
influx of inflammatory cells (31% reduction; p < 0.05)
into the joint cavity following OLT1177 treatment
(Fig. 3c, d). Synovial tissue extracts were analyzed for
cytokine and chemokine concentrations. As depicted in
Fig. 3e–h, there were significant reductions in IL-1β
(69%; p = 0.004), IL-6 (70%; p < 0.001), myeloperoxidase
(MPO) (39%; p = 0.006), and CXCL1 (75%; p < 0.001) in
OLT1177-treated mice. Thus, OLT1177 reduced the
local level of inflammatory mediators, which were asso-
ciated with a significant amelioration in joint swelling in
this model of MSU-induced gouty arthritis.
Therapeutic administration of OLT1177 suppresses MSU-
induced gouty arthritis
Next, we evaluated the effect of oral administration of
OLT1177 after the onset of arthritis to explore a thera-
peutic treatment strategy. Mice were injected i.a. with
MSU crystals to elicit arthritis. One hour thereafter, mice
received a single oral dose of OLT1177 (600 mg/kg) and
were killed 3 hours later. As depicted in Fig. 4a and b,
OLT1177-treated mice showed a trend toward reduced
a
b
Fig. 2 Dose-dependent effects of OLT1177 on mice subjected to
zymosan-induced arthritis. a Mean ± SEM of joint score (n = 10) in
mice treated with 60, 200, or 600 mg/kg of OLT1177. b Plasma
levels (μg/ml) of OLT1177 in mice (n = 4–5 per group) treated
with 60 (p < 0.01), 200 (p < 0.0001), or 600 mg/kg (p < 0.0001) of
OLT1177. # 600 mg/kg vs 200 mg/kg, *** p < 0.001, ** p < 0.01,
p < 0.05
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total circulating leukocytes (p = 0.09) and a signifi-
cant reduction in monocytes (− 45%; p < 0.01) and
granulocytes (− 38%; p < 0.05). Whole-blood cultures
revealed that spontaneous IL-6 production by circu-
lating WBCs was lower in OLT1177-treated mice
than in the vehicle-treated group (Fig. 4c) (p < 0.05).
Joints from mice treated with OLT1177 exhibited
markedly reduced macroscopic joint inflammation
(Fig. 4d) (p < 0.0001). In addition, in the synovial tis-
sue extracts, IL-1β (44%; p = 0.0002), IL-6 (30%; p <






Fig. 3 Effect of oral treatment with OLT1177 in monosodium urate (MSU)-induced arthritis. a Representative images of joints of saline-injected
knee (Saline) and from vehicle-treated and OLT1177 (600 mg/kg)-treated mice. b Mean ± SEM of joint score (n = 20). c H&E-stained histological
knee joint sections from vehicle- or OLT1177-treated mice. Original magnification 100 ×. d Mean ± SEM of cell influx (n = 10). e–h Mean ± SEM of
interleukin (IL)-1β, IL-6, myeloperoxidase (MPO), and chemokine (C-X-C motif) ligand 1 (CXCL1) in synovial tissue lysates from mice subjected to
experimental MSU-induced arthritis. n = 10 per group. **** p < 0.0001, *** p < 0.001, ** p < 0.01, * p < 0.05
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We next investigated the effect of OLT1177 treatment
on the activation of the mitogen-activated protein kinase
family member JNK. As depicted in Fig. 4h, phosphory-
lated JNK in synovial extracts from mice treated with
OLT1177 was lower than in vehicle-treated mice. Reduc-
tion in IL-1β in synovial lysates was also confirmed by
Western blot analysis, with reduced levels of the mature
form of IL-1β (p17) in OLT1177-treated mice when
compared with the vehicle-treated mice (Fig. 4h).
OLT1177 treatment in daily food reduces MSU-induced
gouty arthritis
We designed a study of OLT1177 treatment to resemble
an option for patients with recurrent gout attacks. Mice
were fed an OLT1177-enriched diet (7.5 g of OLT1177
per kilogram of food) or a standard research diet for 3
weeks. All mice were then challenged i.a. with MSU
crystals and killed after 4 hours. Figure 5a reveals signifi-
cantly lower joint inflammation scores in mice fed the
OLT1177 diet than in mice fed standard food. Concen-
trations of cytokines in the synovial tissue explants were
significantly reduced for IL-1β (− 47%) and IL-6 (− 37%)
(p < 0.05) in mice fed the OLT1177 diet compared with
mice fed the standard diet (Fig. 5b, c). Both the IL-1β
precursor and the active form of IL-1β (p17) were re-
duced in OLT1177-treated mice, as shown by Western
blot analysis (Fig. 5d). No significant differences were
measured in NLRP3 protein level between the two
groups (Fig. 5d). Gene expression of Nlrp3 and Il1b from
synovial tissue extracts was reduced in the OLT1177
diet-fed mice compared with mice fed the standard diet
(Fig. 5e, f ).
Comparative analysis of plasma OLT1177 concentrations
following food intake in mice and in human phase I study
We next determined the concentration of OLT1177 in
the plasma of mice fed the OLT1177-enriched diet for 3
weeks. During the entire duration of the study, mice had
access to water and food ad libitum and were not sub-
jected to any challenge. Figure 6a shows that mice fed
the OLT1177-enriched diet reached a mean plasma
OLT1177 concentration of 46.3 ± 3.15 μg/ml. Plasma
OLT1177 exposure in humans was measured in a phase
I clinical study in healthy subjects as described elsewhere
[16]. Following a single oral dose of 1000 mg of
OLT1177, the mean maximum plasma concentration
(Cmax) was 32 ± 9.1 μg/ml (Fig. 6b). Plasma OLT1177 ex-





Fig. 4 Effect of posttreatment of oral OLT1177 in monosodium urate-induced arthritis. Total white blood cell (WBC) count (a) and differential
counts (b) in mice treated with vehicle or OLT1177 (600 mg/kg) (n = 5). c Mean ± SEM of spontaneous (Spnt) interleukin (IL)-6 levels from whole-
blood culture in vehicle- and OLT1177-treated mice. d Mean ± SEM of joint score (n = 20). e–g Mean ± SEM of IL-1β, IL-6, and chemokine (C-X-C
motif) ligand 1 (CXCL1) in synovial tissue extracts (n = 10 per group). h Western blot of phospho-c-Jun N-terminal kinase (JNK) and IL-1β (p17 and
IL-1β precursor p37) in synovial tissue extracts. Each lane represents a single mouse. **** p < 0.0001, ** p < 0.01, * p < 0.05. SAPK Stress-activated
protein kinase
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repeated daily oral dosing for 8 consecutive days. The
mean group Cmax after eight consecutive doses of
1000 mg was 41.4 ± 10.8 μg/ml (Fig. 6b). The mean
OLT1177 plasma level in mice following 3 weeks of
OLT1177-enriched diet reached the same order of mag-
nitude as the level reached in humans.
Discussion
In the current study, we describe the anti-inflammatory
effects of the synthetic small molecule sulfonyl nitrile
compound OLT1177 in two different mouse models of
experimental arthritis representative of reactive arthritis
and gouty arthritis. As previously reported, OLT1177 in
humans is safe, orally active, and specifically inhibits the
NLRP3 inflammasome, preventing processing and re-
lease of active IL-1β [16]. The favorable phase I safety
profile of OLT1177 combined with the reported inhibi-
tory effects on NLRP3 inflammasome and IL-1β release
led to approval of the molecule for phase II development
in gout.
OLT1177 treatment administered either intraperito-
neally or by oral gavage reduced joint inflammation
in zymosan-induced arthritis when compared with
vehicle-treated mice. We observed a significant reduc-
tion in the level of inflammatory cytokines in synovial
tissue explants, including IL-1β and IL-6. Prolonged
neutrophil activity, as in chronic inflammatory condi-
tions, leads to detrimental effects [23]. In the present
study, we have shown that treatment with OLT1177
suppressed cell infiltration into the joint with reduced
levels of the neutrophil chemokine CXCL1 in synovial
tissue extracts. These data and the reduced knee
swelling in the OLT1177-treated mice are representa-
tive of the benefits of IL-1 inhibition, also observed
in previous studies of reactive arthritis [7, 24].
OLT1177 is a specific NLRP3 inflammasome inhibitor
[16]. Zymosan contains β-glucan from the cell wall of
the yeast (S. cerevisiae), and this glucan induces NLRP3
inflammasome activation [25]. In the present study, we
have demonstrated that OLT1177 reduces the severity of
zymosan-induced arthritis in a dose-dependent manner
by intraperitoneal administration and via oral gavage in
mice. The lack of effect of OLT1177 treatment on
TNF-α production supports previously observed data
[16] confirming that OLT1177 primarily targets IL-1β.
We observed a direct correlation between the doses
60, 200, and 600 mg/kg of OLT1177 and the reduction




Fig. 5 Effect of OLT1177-enriched diet in monosodium urate (MSU)-induced arthritis. a Mean ± SEM of joint score (n = 9–10). b and c Mean ± SEM of
interleukin (IL)-1β and IL-6 in synovial tissue lysates from mice subjected to experimental MSU-induced arthritis (n = 9–10 per group). d Western blot
for NLRP3 and IL-1β (p17 and IL-1β precursor p37) in synovial tissue lysates from mice subjected to experimental MSU-induced arthritis and fed a
standard diet or an OLT1177-enriched diet. Each lane represents a single mouse. e and f Fold change of messenger RNA (mRNA) levels of nlrp3 and
il1b of synovial tissue extracts from mice treated with OLT1177 (n = 4–5 per group). **** p < 0.0001, ** p < 0.01, * p < 0.05
a b
Fig. 6 Comparison of plasma OLT1177 levels in mice and
humans. a Mean ± SEM of OLT1177 resting plasma level (μg/ml)
of mice fed for 3 weeks with standard and OLT1177-enriched
diets (n = 5). b Mean ± SEM of maximum concentration (Cmax) of
resting plasma levels of OLT1177 in healthy human subjects
following a single dose (n = 5) and after eight daily oral doses
(n = 5) of OLT1177 (16 mg/kg). Figure 6b is adapted from [16]
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and − 63%, p < 0.0001, respectively). In comparison, hu-
man exposure after oral administration of OLT1177 led
to an average Cmax of 41.4 ± 10.8 μg/ml after 1000 mg/d
for 8 consecutive days [16], which is of the same order
of magnitude achieved in the 600 mg/kg dose group.
Thus, the OLT1177 exposure used in this study, which
was shown to be effective in reducing the severity of
zymosan-induced arthritis in a mouse model, reached
plasma levels similar to those observed in humans, with
no significant adverse effects [16].
Gouty arthritis is a specific form of inflammatory arth-
ritis with elevated urate levels in the bloodstream [3, 26].
In this condition, formation and deposition of MSU
crystals in the synovial space cause acute inflammation
due to neutrophil infiltration. Acute gout manifestations
include attacks of severe pain, stiffness, and swelling of a
distal joint, with great impact on patient quality of life
[27]. In the present study, we have demonstrated that
oral treatment with OLT1177 reduced joint swelling and
infiltration of inflammatory cells in a murine model of
gouty arthritis simulated by administration of MSU
crystals into the articular space. Compared with the
vehicle-treated group, mice treated with OLT1177 exhib-
ited significant reductions in IL-1β, IL-6, MPO, and
CXCL1 levels in extracted synovial membranes. These
data support the therapeutic potential of the use of
OLT1177 in gout, an IL-1β-mediated disease [4, 28].
In this study, treatment with OLT1177 was consist-
ently associated with a reduction in IL-6. Although the
properties of IL-6 during an acute-phase response are
well known, the role of IL-6 in gout remains unclear.
Mokuda et al. showed that treatment with tocilizumab
improved clinical symptoms in a patient with systemic
tophaceous gout [29]. Pinto et al. showed the benefit of
tocilizumab treatment in another case of gouty arthritis
not responding to the nonsteroidal anti-inflammatory
drugs colchicine and allopurinol [30]. However, unlike
IL-1β blockade, there are no randomized clinical trials of
tocilizumab in refractory gout. It is likely that the in-
crease in IL-6 in gout is a biomarker for active IL-1β. In
fact, the ability of IL-1β to induce IL-6 is long estab-
lished, and elevated IL-6 is often used as a surrogate
marker for subpicogram levels of IL-1β in humans. In
mice, IL-6 is decreased by genetic and pharmacologic in-
hibition of IL-1 in gouty arthritis [31]. Further, IL-6
functions as a marker in inflammasome-mediated inflam-
mation with no direct role in MSU-induced inflammation
[32]. The acute inflammation of arthritis induced by zy-
mosan is IL-6-independent [33]. In the present study, the
reduction in IL-6 is likely due to OLT1177-mediated
IL-1β reduction as a consequence of the NLRP3 inflam-
masome inhibition.
We also evaluated the anti-inflammatory effect of
therapeutically administrated OLT1177. To this end, we
designed a study that mimics a clinical setting where a
subject begins treatment after the onset of clinical dis-
ease. Mice were subjected to an i.a. injection of MSU
crystals, and after 1 hour, vehicle or OLT1177 was
administrated as a single oral dose. Mice were killed 3
hours following treatment. A single dose of OLT1177
given therapeutically reduced joint inflammation as well
as IL-1β, IL-6, and CXCL1 concentrations in the ex-
tracted synovial tissue. The anti-inflammatory properties
of OLT1177 treatment in the MSU-induced arthritis
model were also confirmed with the reduction in the
phosphorylation of JNK, which has been implicated in
the pathophysiology of several forms of arthritis, such as
rheumatoid arthritis and gouty arthritis [34–36].
Patients with recurrent attacks of gout have been
treated chronically with IL-1β-blocking therapies (anakinra
[37, 38], canakinumab [39, 40], or rilonacept [41, 42]) and
have significantly reduced attack rates. Considering the
safety profile of oral OLT1177 in humans [16], we designed
a study of prolonged oral OLT1177 exposure. Mice were
fed a standard diet or an OLT1177-enriched diet for 3
weeks before i.a. injection of MSU crystals into the joints.
Joint inflammation and inflammatory markers were re-
duced in the mice fed an OLT1177 diet when compared
with the standard diet group. In addition, Western blot ana-
lysis of the synovial membranes revealed a reduction in
IL-1β precursor (p37) as well as the mature form of IL-1β
(p17) with no change in NLRP3 protein level. These data
are consistent with the autopositive feedback of IL-1, where
IL-1 induces IL-1 [43]. Thus, we postulate that chronic
OLT1177-mediated suppression of active IL-1β production
interrupted IL-1β-induced IL-1β precursor synthesis and
not solely the NLRP3-dependent release of bioactive IL-1β
and the downstream effect of IL-1β.
The unchanged NLRP3 protein level between the two
treatment groups indicates that OLT1177 does not
reduce inflammasome protein levels in the short-term
model (4 hours). We previously reported that there is no
reduction in NLRP3 in cells treated in vitro with OLT1177
[16]. However, we did observe reduced Nlrp3 gene expres-
sion in the OLT1177-enriched diet group compared with
the standard diet mice. Because messenger RNA was ex-
tracted from whole synovial tissue, the reduction in Nlrp3
gene expression likely reflects a reduction of cell influx
into the synovial membrane in the OLT1177-treated mice.
Alternatively, OLT1177 in the food may have reduced
gene expression of Nlrp3 during the 3 weeks of the
enriched diet. Mean plasma levels of OLT1177 after the 3
weeks was 46.3 ± 3.15 μg/ml (347 μM). In humans, after
8 days of oral OLT1177, the mean plasma level was
41.4 μg/ml (311 μM). In vitro, the half maximal inhibitory
concentration of OLT1177 for IL-1β secretion was 1 μM
for human blood monocyte-derived macrophages [16].
Thus, on the basis of efficacy in vitro, OLT1177 reaches
Marchetti et al. Arthritis Research & Therapy  (2018) 20:169 Page 9 of 11
plasma levels 300-fold greater than those needed to re-
duce IL-1β secretion in primary human cells.
Conclusions
There is a growing body of research substantiating the
mechanism and efficacy of NLRP3 inflammasome inhibi-
tors in experimental animal models, including acute
arthritides. However, no approved human agents are
available. The small and orally active molecule OLT1777
inhibits the formation of the NLRP3 inflammasome and
reduces the severity of reactive and gouty arthritis. On
the basis of evidence described in this study and the
favorable phase I safety profile, oral OLT1177 has
advanced into three phase II development programs,
including gout, establishing the translational value of
OLT1177 as a safe oral NLRP3 inhibitor.
Additional file
Additional file 1: Figure S1. Effect of oral treatment with OLT1177 in
zymosan-induced arthritis. a Mean ± SEM of joint score (n = 8). b and c
Mean ± SEM of IL-1β and TNF-α in synovial tissue extracts from mice
subjected to experimental zymosan-induced arthritis and treated with
OLT1177 (600 mg/kg) (n = 4 per group). **** p < 0.0001, * p < 0.05 vs
vehicle. (DOCX 47 kb)
Abbreviations
Cmax: Maximum plasma concentration ; CXCL1: Chemokine (C-X-C motif)
ligand 1; GC: Gas chromatography; i.a.: Intra-articularly; IL-18: Interleukin 18;
IL-1β: Interleukin 1β; IL-6: Interleukin 6; IL-8: Interleukin 8; JNK: c-Jun N-
terminal kinase; MPO: Myeloperoxidase; mRNA: Messenger RNA;
MSU: Monosodium urate; NLR: Nucleotide-binding oligomerization domain-
like receptor; NLRP3: NACHT, LRR and PYD domains-containing protein 3;
rINN: Recommended International Nonproprietary Name; SAPK: Stress-
activated protein kinase; TNF-α: Tumor necrosis factor-α; WBC: White blood cell
Acknowledgements
The authors thank Niklas Lonnemann.
Funding
These studies are supported by National Institutes of Health grant AI-15614 (to
CAD), the Interleukin Foundation for Medical Research, and Olatec Industries.
Availability of data and materials
All the data generated and analyzed during this study are included in this
published article and are available from the authors.
Authors’ contributions
CAD, CM, and LABJ designed the study and wrote the manuscript. BS, CM, NP,
DMdG, IWT, MIK, and TA performed research, analyzed or interpreted results,
and edited the manuscript. All authors read and approved the final manuscript.
Ethics approval
The animal protocols of this study were approved by the University of




CAD serves as chair of Olatec’s Scientific Advisory Board, is co-chief scientific
officer, and receives compensation from Olatec. LABJ serves on Olatec’s
Scientific Advisory Board and receives compensation from Olatec. The other
authors declare that they have no competing interests.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1Department of Medicine, University of Colorado Denver, Aurora, CO, USA.
2Department of Rheumatology, Radboud University Medical Center,
Nijmegen, The Netherlands. 3Department of Internal Medicine and Radboud
Institute of Molecular Life Sciences (RIMLS), Radboud University Medical
Center, Geert Grooteplein Zuid 8, 6525, GA, Nijmegen, The Netherlands.
Received: 3 April 2018 Accepted: 9 July 2018
References
1. Joosten LA, Netea MG, Mylona E, Koenders MI, Malireddi RK, Oosting M,
Stienstra R, van de Veerdonk FL, Stalenhoef AF, Giamarellos-Bourboulis EJ, et
al. Engagement of fatty acids with Toll-like receptor 2 drives interleukin-1β
production via the ASC/caspase 1 pathway in monosodium urate
monohydrate crystal-induced gouty arthritis. Arthritis Rheum. 2010;62(11):
3237–48.
2. Carter JD, Hudson AP. Reactive arthritis: clinical aspects and medical
management. Rheum Dis Clin North Am. 2009;35(1):21–44.
3. Dalbeth N, Merriman TR, Stamp LK. Gout. Lancet. 2016;388(10055):2039–52.
4. So AK, Martinon F. Inflammation in gout: mechanisms and therapeutic
targets. Nat Rev Rheumatol. 2017;13(11):639–47.
5. Dinarello CA. An expanding role for interleukin-1 blockade from gout to
cancer. Mol Med. 2014;20(Suppl 1):S43–58.
6. Kuiper S, Joosten LA, Bendele AM, Edwards CK 3rd, Arntz OJ, Helsen MM,
Van de Loo FA, Van den Berg WB. Different roles of tumour necrosis factor
α and interleukin 1 in murine streptococcal cell wall arthritis. Cytokine. 1998;
10(9):690–702.
7. van de Loo FA, Joosten LA, van Lent PL, Arntz OJ, van den Berg WB. Role of
interleukin-1, tumor necrosis factor α, and interleukin-6 in cartilage
proteoglycan metabolism and destruction: effect of in situ blocking in murine
antigen- and zymosan-induced arthritis. Arthritis Rheum. 1995;38(2):164–72.
8. Dinarello CA. Interleukin-1 in the pathogenesis and treatment of
inflammatory diseases. Blood. 2011;117(14):3720–32.
9. O’Neill LA. The interleukin-1 receptor/toll-like receptor superfamily: 10 years
of progress. Immunol Rev. 2008;226:10–8.
10. Bertazzolo N, Punzi L, Pianon M, Cesaro G, Todesco S. Interrelationship
between interleukin 8 and neutrophils in synovial fluid of crystal induced
arthritis. J Rheumatol. 1994;21(9):1776–7.
11. Joosten LA, Koenders MI, Smeets RL, Heuvelmans-Jacobs M, Helsen MM,
Takeda K, Akira S, Lubberts E, van de Loo FA, van den Berg WB. Toll-like
receptor 2 pathway drives streptococcal cell wall-induced joint
inflammation: critical role of myeloid differentiation factor 88. J Immunol.
2003;171(11):6145–53.
12. Martinon F. Mechanisms of uric acid crystal-mediated autoinflammation.
Immunol Rev. 2010;233(1):218–32.
13. Martinon F, Petrilli V, Mayor A, Tardivel A, Tschopp J. Gout-associated uric acid
crystals activate the NALP3 inflammasome. Nature. 2006;440(7081):237–41.
14. Schroder K, Zhou R, Tschopp J. The NLRP3 inflammasome: a sensor for
metabolic danger? Science. 2010;327(5963):296–300.
15. Franchi L, Eigenbrod T, Munoz-Planillo R, Nunez G. The inflammasome: a
caspase-1-activation platform that regulates immune responses and disease
pathogenesis. Nat Immunol. 2009;10(3):241–7.
16. Marchetti C, Swartzwelter B, Gamboni F, Neff CP, Richter K, Azam T, Carta S,
Tengesdal I, Nemkov T, D’Alessandro A, et al. OLT1177, a β-sulfonyl nitrile
compound, safe in humans, inhibits the NLRP3 inflammasome and reverses
the metabolic cost of inflammation. Proc Natl Acad Sci U S A. 2018;115(7):
E1530–9.
17. Hoffman HM, Throne ML, Amar NJ, Sebai M, Kivitz AJ, Kavanaugh A,
Weinstein SP, Belomestnov P, Yancopoulos GD, Stahl N, et al. Efficacy and
safety of rilonacept (interleukin-1 trap) in patients with cryopyrin-associated
periodic syndromes: results from two sequential placebo-controlled studies.
Arthritis Rheum. 2008;58(8):2443–52.
18. Stankovic Stojanovic K, Delmas Y, Torres PU, Peltier J, Pelle G, Jeru I,
Colombat M, Grateau G. Dramatic beneficial effect of interleukin-1 inhibitor
treatment in patients with familial Mediterranean fever complicated with
amyloidosis and renal failure. Nephrol Dial Transplant. 2012;27(5):1898–901.
Marchetti et al. Arthritis Research & Therapy  (2018) 20:169 Page 10 of 11
19. Schlesinger N. Anti-interleukin-1 therapy in the management of gout. Curr
Rheumatol Rep. 2014;16(2):398.
20. So A, Dumusc A, Nasi S. The role of IL-1 in gout: from bench to bedside.
Rheumatology (Oxford). 2018;57(Suppl 1):i12–9.
21. Schlesinger N, De Meulemeester M, Pikhlak A, Yucel AE, Richard D, Murphy
V, Arulmani U, Sallstig P, So A. Canakinumab relieves symptoms of acute
flares and improves health-related quality of life in patients with difficult-to-
treat gouty arthritis by suppressing inflammation: results of a randomized,
dose-ranging study. Arthritis Res Ther. 2011;13(2):R53.
22. Fels E, Sundy JS. Refractory gout: what is it and what to do about it? Curr
Opin Rheumatol. 2008;20(2):198–202.
23. Soehnlein O, Steffens S, Hidalgo A, Weber C. Neutrophils as protagonists
and targets in chronic inflammation. Nat Rev Immunol. 2017;17(4):248–61.
24. Cavalli G, Koenders M, Kalabokis V, Kim J, Choon Tan A, Garlanda C,
Mantovani A, Dagna L, Joosten LAB, Dinarello CA. Treating experimental
arthritis with the innate immune inhibitor interleukin-37 reduces joint and
systemic inflammation. Rheumatology (Oxford). 2017;56(12):2256.
25. Kumar H, Kumagai Y, Tsuchida T, Koenig PA, Satoh T, Guo Z, Jang MH,
Saitoh T, Akira S, Kawai T. Involvement of the NLRP3 inflammasome in
innate and humoral adaptive immune responses to fungal β-glucan. J
Immunol. 2009;183(12):8061–7.
26. McCarty DJ, Hollander JL. Identification of urate crystals in gouty synovial
fluid. Ann Intern Med. 1961;54:452–60.
27. Duff GW, Atkins E, Malawista SE. The fever of gout: urate crystals activate
endogenous pyrogen production from human and rabbit mononuclear
phagocytes. Trans Assoc Am Phys. 1983;96:234–45.
28. Dinarello CA, Simon A, van der Meer JW. Treating inflammation by blocking
interleukin-1 in a broad spectrum of diseases. Nat Rev Drug Discov. 2012;
11(8):633–52.
29. Mokuda S, Kanno M, Takasugi K, Okumura C, Ito Y, Masumoto J. Tocilizumab
improved clinical symptoms of a patient with systemic tophaceous gout
who had symmetric polyarthritis and fever: an alternative treatment by
blockade of interleukin-6 signaling. SAGE Open Med Case Rep. 2014;2:
2050313X13519774.
30. Pinto JL, Mora GE, Fernández-Avila DG, Gutiérrez JM, Díaz MC, Grupo
Javeriano de Investigacion en Enfermedades Reumáticas. Tocilizumab in a
patient with tophaceous gout resistant to treatment. Reumatol Clin. 2013;
9(3):178–80.
31. Torres R, Macdonald L, Croll SD, Reinhardt J, Dore A, Stevens S, Hylton DM,
Rudge JS, Liu-Bryan R, Terkeltaub RA, et al. Hyperalgesia, synovitis and
multiple biomarkers of inflammation are suppressed by interleukin 1
inhibition in a novel animal model of gouty arthritis. Ann Rheum Dis. 2009;
68(10):1602–8.
32. McGeough MD, Pena CA, Mueller JL, Pociask DA, Broderick L, Hoffman HM,
Brydges SD. Cutting edge: IL-6 is a marker of inflammation with no direct
role in inflammasome-mediated mouse models. J Immunol. 2012;189(6):
2707–11.
33. van de Loo FA, Kuiper S, van Enckevort FH, Arntz OJ, van den Berg WB.
Interleukin-6 reduces cartilage destruction during experimental arthritis: a
study in interleukin-6-deficient mice. Am J Pathol. 1997;151(1):177–91.
34. Guma M, Ronacher LM, Firestein GS, Karin M, Corr M. JNK-1 deficiency limits
macrophage-mediated antigen-induced arthritis. Arthritis Rheum. 2011;63(6):
1603–12.
35. Han Z, Boyle DL, Chang L, Bennett B, Karin M, Yang L, Manning AM,
Firestein GS. C-Jun N-terminal kinase is required for metalloproteinase
expression and joint destruction in inflammatory arthritis. J Clin Invest. 2001;
108(1):73–81.
36. Thalhamer T, McGrath MA, Harnett MM. MAPKs and their relevance to
arthritis and inflammation. Rheumatology (Oxford). 2008;47(4):409–14.
37. Ghosh P, Cho M, Rawat G, Simkin PA, Gardner GC. Treatment of acute
gouty arthritis in complex hospitalized patients with anakinra. Arthritis Care
Res (Hoboken). 2013;65(8):1381–4.
38. So A, De Smedt T, Revaz S, Tschopp J. A pilot study of IL-1 inhibition by
anakinra in acute gout. Arthritis Res Ther. 2007;9(2):R28.
39. Schlesinger N, Alten RE, Bardin T, Schumacher HR, Bloch M, Gimona A,
Krammer G, Murphy V, Richard D, So AK. Canakinumab for acute gouty
arthritis in patients with limited treatment options: results from two
randomised, multicentre, active-controlled, double-blind trials and their
initial extensions. Ann Rheum Dis. 2012;71(11):1839–48.
40. So A, De Meulemeester M, Pikhlak A, Yucel AE, Richard D, Murphy V,
Arulmani U, Sallstig P, Schlesinger N. Canakinumab for the treatment of
acute flares in difficult-to-treat gouty arthritis: results of a multicenter, phase
II, dose-ranging study. Arthritis Rheum. 2010;62(10):3064–76.
41. Mitha E, Schumacher HR, Fouche L, Luo SF, Weinstein SP, Yancopoulos GD,
Wang J, King-Davis S, Evans RR. Rilonacept for gout flare prevention during
initiation of uric acid-lowering therapy: results from the PRESURGE-2
international, phase 3, randomized, placebo-controlled trial. Rheumatology
(Oxford). 2013;52(7):1285–92.
42. Terkeltaub RA, Schumacher HR, Carter JD, Baraf HS, Evans RR, Wang J, King-
Davis S, Weinstein SP. Rilonacept in the treatment of acute gouty arthritis: a
randomized, controlled clinical trial using indomethacin as the active
comparator. Arthritis Res Ther. 2013;15(1):R25.
43. Dinarello CA, Ikejima T, Warner SJ, Orencole SF, Lonnemann G, Cannon JG,
Libby P. Interleukin 1 induces interleukin 1. I. Induction of circulating
interleukin 1 in rabbits in vivo and in human mononuclear cells in vitro. J
Immunol. 1987;139(6):1902–10.
Marchetti et al. Arthritis Research & Therapy  (2018) 20:169 Page 11 of 11
